Your browser doesn't support javascript.
loading
The effect of older age on outcomes of rTMS treatment for treatment-resistant depression.
Leuchter, Michael K; Citrenbaum, Cole; Wilson, Andrew C; Tibbe, Tristan D; Jackson, Nicholas J; Krantz, David E; Wilke, Scott A; Corlier, Juliana; Strouse, Thomas B; Hoftman, Gil D; Tadayonnejad, Reza; Koek, Ralph J; Slan, Aaron R; Ginder, Nathaniel D; Distler, Margaret G; Artin, Hewa; Lee, John H; Adelekun, Adesewa E; Einstein, Evan H; Oughli, Hanadi A; Leuchter, Andrew F.
Afiliação
  • Leuchter MK; TMS Clinical and Research Program, Neuromodulation Division, Semel Institute for Neuroscience and Human Behavior at UCLA, Los Angeles, CA, USA.
  • Citrenbaum C; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
  • Wilson AC; TMS Clinical and Research Program, Neuromodulation Division, Semel Institute for Neuroscience and Human Behavior at UCLA, Los Angeles, CA, USA.
  • Tibbe TD; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
  • Jackson NJ; Cooperative Institute for Research in Environmental Sciences (CIRES), University of Colorado Boulder, Boulder, CO, USA.
  • Krantz DE; NOAA National Centers for Environmental Information (NCEI), Boulder, CO, USA.
  • Wilke SA; Department of Psychology, University of California, Los Angeles, CA, USA.
  • Corlier J; Department of Medicine Statistics Core, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
  • Strouse TB; Department of Medicine Statistics Core, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
  • Hoftman GD; TMS Clinical and Research Program, Neuromodulation Division, Semel Institute for Neuroscience and Human Behavior at UCLA, Los Angeles, CA, USA.
  • Tadayonnejad R; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
  • Koek RJ; TMS Clinical and Research Program, Neuromodulation Division, Semel Institute for Neuroscience and Human Behavior at UCLA, Los Angeles, CA, USA.
  • Slan AR; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
  • Ginder ND; TMS Clinical and Research Program, Neuromodulation Division, Semel Institute for Neuroscience and Human Behavior at UCLA, Los Angeles, CA, USA.
  • Distler MG; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
  • Artin H; TMS Clinical and Research Program, Neuromodulation Division, Semel Institute for Neuroscience and Human Behavior at UCLA, Los Angeles, CA, USA.
  • Lee JH; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
  • Adelekun AE; TMS Clinical and Research Program, Neuromodulation Division, Semel Institute for Neuroscience and Human Behavior at UCLA, Los Angeles, CA, USA.
  • Einstein EH; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
  • Oughli HA; TMS Clinical and Research Program, Neuromodulation Division, Semel Institute for Neuroscience and Human Behavior at UCLA, Los Angeles, CA, USA.
  • Leuchter AF; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Int Psychogeriatr ; : 1-6, 2024 Mar 25.
Article em En | MEDLINE | ID: mdl-38525670
ABSTRACT
Clinical outcomes of repetitive transcranial magnetic stimulation (rTMS) for treatment of treatment-resistant depression (TRD) vary widely and there is no mood rating scale that is standard for assessing rTMS outcome. It remains unclear whether TMS is as efficacious in older adults with late-life depression (LLD) compared to younger adults with major depressive disorder (MDD). This study examined the effect of age on outcomes of rTMS treatment of adults with TRD. Self-report and observer mood ratings were measured weekly in 687 subjects ages 16-100 years undergoing rTMS treatment using the Inventory of Depressive Symptomatology 30-item Self-Report (IDS-SR), Patient Health Questionnaire 9-item (PHQ), Profile of Mood States 30-item, and Hamilton Depression Rating Scale 17-item (HDRS). All rating scales detected significant improvement with treatment; response and remission rates varied by scale but not by age (response/remission ≥ 60 38%-57%/25%-33%; <60 32%-49%/18%-25%). Proportional hazards models showed early improvement predicted later improvement across ages, though early improvements in PHQ and HDRS were more predictive of remission in those < 60 years (relative to those ≥ 60) and greater baseline IDS burden was more predictive of non-remission in those ≥ 60 years (relative to those < 60). These results indicate there is no significant effect of age on treatment outcomes in rTMS for TRD, though rating instruments may differ in assessment of symptom burden between younger and older adults during treatment.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Int Psychogeriatr Assunto da revista: GERIATRIA / PSIQUIATRIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Int Psychogeriatr Assunto da revista: GERIATRIA / PSIQUIATRIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos